LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Agile Therapeutics, Inc. (“Agile” or the “Company”) (Nasdaq: AGRX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Agile shares between March 9, 2016 and January 3, 2017 inclusive (the “Class Period”) are encouraged to contact the firm in advance of the March 7, 2017 lead plaintiff motion deadline.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
Agile is a pharmaceutical company that develops and sells prescription female contraceptive products.
On January 3, 2017, the Company disclosed new data regarding its Phase 3 SECURE study assessing Agile’s combined hormonal contraceptive patch product, Twirla. The FDA requested the study after it rejected Agile's first marketing application in 2013.
The Company stated that nearly 2% of study participants suffered "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Furthermore, 51.4% of subjects dropped out of the study. When this information was released to the investing public, the value of Agile stock fell, causing investors severe harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.